Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Pinealoma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Liver Neoplasms 1Head and Neck Neoplasms 1Glioma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Stem Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 12Rituximab 10Peripheral Blood Stem Cell Transplantation 8fludarabine phosphate 7Etoposide 5fludarabine 4Radiotherapy 4Filgrastim 4Cytarabine 4venetoclax 3ofatumumab 3Whole-Body Irradiation 3Vincristine 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Doxorubicin 3Cyclosporine 3Carmustine 3Bendamustine Hydrochloride 3sargramostim 2romidepsin 2idelalisib 2ibrutinib 2ibritumomab tiuxetan 2Saline Solution 2Prednisone 2Pentetic Acid 2Ondansetron 2O(6)-benzylguanine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Non-Hodgkin × temsirolimus × Clear all
NCT01170052 2011-03-16

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Charite University, Berlin, Germany

Phase 1/2 Withdrawn
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡